Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-1,398,795
Closed -$7.99M 133
2020
Q4
$7.99M Sell
1,398,795
-167,326
-11% -$1.06M 0.03% 79
2020
Q3
$10.4M Sell
1,566,121
-73,000
-4% -$650K 0.04% 66
2020
Q2
$14.5M Buy
+1,639,121
New +$4.71M 0.06% 52
2015
Q3
Sell
-75,495
Closed -$1.72M 136
2015
Q2
$1.72M Sell
75,495
-2,976
-4% -$73.1K 0.02% 111
2015
Q1
$1.99M Sell
78,471
-22,157
-22% -$610K 0.02% 107
2014
Q4
$2.48M Hold
100,628
0.03% 98
2014
Q3
$2.73M Hold
100,628
0.03% 81
2014
Q2
$3.15M Hold
100,628
0.04% 82
2014
Q1
$6.76M Sell
100,628
-2,110
-2% -$130K 0.09% 61
2013
Q4
$4.74M Buy
+102,738
New +$4.52M 0.07% 66

Other funds holding VXRT

Baker Bros. Advisors's VXRT Position: Q1 2021 in Review

Baker Bros. Advisors sold out of Vaxart (VXRT) in Q1 2021, closing a stake of 1,398,795 shares — an estimated $7.99M sold.

Baker Bros. Advisors first reported a position in VXRT in Q4 2013 and held it in 10 quarters. The position peaked at $14.5M in Q2 2020. 159 funds tracked by Wall St. Rank hold VXRT as of Q1 2021.

  • Baker Bros. Advisors reported no remaining Vaxart position as of Q1 2021 after selling out during the quarter.
  • Baker Bros. Advisors sold 1,398,795 Vaxart shares in Q1 2021, an estimated $7.99M.
  • Baker Bros. Advisors first reported a position in Vaxart in Q4 2013 and held it in 10 quarters.
  • Baker Bros. Advisors's Vaxart position peaked at $14.5M in Q2 2020.
  • 159 funds tracked by Wall St. Rank held Vaxart as of Q1 2021.

Based on Baker Bros. Advisors's 13F filing for Q1 2021, filed 17 May 2021.